SCA
DCPH

Snowden Capital Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Snowden Capital Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-94
Closed – – 2144
2021
Q4 		$0 Buy
+94
New +$1.77K ﹤0.01% 2183

Other funds holding DCPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Snowden Capital Advisors's DCPH Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2022, closing a stake of 94 shares.

Snowden Capital Advisors first reported a position in DCPH in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 123 funds tracked by Wall St. Rank hold DCPH as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 94 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $0 in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.